Annovis Bio, Inc. (ANVS): Total Liabilities
$4.23M
As of 2025-12-31
$26.29M
As of 2026-06-30
-18.1%
3-year compound annual growth
+48.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.23M | -8.4% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $4.62M | -74.3% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $17.96M | +133.3% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $7.70M | n/a | 2024-03-29, Balance as of period end |
| 2022-09-30 | $2.53M | n/a | 2023-03-31, Balance as of period end |
| 2022-06-30 | $1.30M | n/a | 2023-03-31, Balance as of period end |
| 2022-03-31 | $1.40M | n/a | 2023-03-31, Balance as of period end |
| 2021-12-31 | $1.51M | +160.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $578.4K | -77.9% | 2022-03-02, Balance as of period end |
| 2019-12-31 | $2.62M | n/a | 2021-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $4.23M | -8.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare ANVS, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗